以上、以下；以上以下

以上以下

WO2016044334(特表2017-528480)
"1. A stable aqueous pharmaceutical formulation, the formulation comprising a monoclonal antibody, trehalose, and a buffer, wherein the weight ratio of said monoclonal antibody to said trehalose in the formulation is greater than or equal to（以上）0.41 and less than（未満）1.65, wherein the formulation has a pH of about 5.5 to about 7.0, and wherein the monoclonal antibody binds VEGF."

WO2016007664(特表2017-525676)
"23. The nanoparticulate carrier formulation of claim 1 , wherein the nanoparticles have an average diameter in the range from about 10 nm to（の範囲）about 30 nm."

WO2015066444(特表2016-535777)
"8. The pharmaceutical composition of claim 1 , wherein the ratio of the weight of the loteprednol etabonate to the weight of the surface-altering agent present in the pharmaceutical composition is greater than or equal to（以上）about 1 : 1, and less than or equal to（以下）about 3: 1."

WO2016048765(特表2017-533293)
"5. The method of any previous Claim, the method further characterized by the nonionic surfactant and the anionic surfactant each independently being present at a concentration of 0.01 weight-percent or more（以上）and ten weight-percent or less（以下）based on total aqueous solution weight."

WO2014110012(特表2016-511647)
"3. The microfluidic device of claim 2, wherein the first substrate has a thickness of no less than（以上）50 microns and no greater than（以下）10 millimeters."

WO2014035679(特表2015-535389)
"10. The method according to claim 1 , wherein the activating step occurs using microwave at a frequency greater than or equal to（以上）about 1.5 Ghz and less than or equal to（以下）about 8.5 GHz."

WO2014014798(特表2015-527970)
"12. The glass article of claim 11, wherein a ratio of Fe₂0₃ (mol.%) to Ti0₂(mol.%) is greater than or equal to（以上）about 0.52 and less than or equal to（以下）about 1.22.”